SUMMARY
In this paper the data about antimicrobial resistance mechanisms of Pseudomonas aeruginosa against different antibiotics have been analysed. It was shown that, Pseudomonas aeruginosa is a conditionally pathogenic microorganism, the causative agent of sapronosis infection, a leading cause of morbidity and mortality in patients with cystic fibrosis and immunocompromised individuals. Due to their ability to easily adapt to the external environment, Pseudomonas aeruginosa strains are often the cause of hospital infections. Antibiotic resistance in P.aeruginosa is multifactorial, as it can arise through innate, acquired, or adaptive mechanisms. New therapeutic approaches, such as quorum sensing, phage therapy, and the use of nanoparticles, have shown significant antimicrobial effects against antibiotic-resistant strains of P.aeruginosa in vitro.
Keywords: Pseudomonas aeruginosa, antimicrobial resistance, opportunistic infections, resistance mechanisms

---

REFERENCES

1. Яновская Д.И. Устойчивость Pseudomonas aeruginosa к антибиотикам: механизмы формирования и возможные альтернативные терапевтические стратегии / Актуальные проблемы современной медицины и фармации 2022: сб. материалов докл. LXXVI Междунар. науч-практ. конф. студентов и молодых ученых, Минск, 20-21 апреля. 2022 г, с.802-806 https://rep.bsmu.by/handle/BSMU/39753
2. Catalano A., Iacopetta D., Ceramella J. Multidrug resistance (MDR): a widespread phenomenon in pharmacological therapies // Molecules, 2022,27(3),р.616. doi: 10.3390/molecules27030616
3. Bloom D., Black S., Salisbury D., Rappuoli R. Antimicrobial resistance and the role of vaccines // Proc. Natl. Acad. Sci. USA., 2018,115(51);p.12868-12871 doi: 10.1073/pnas.1717157115
4. Billamboz M., Fatima Z., Hameed S., Jawhara S. Promising Drug Candidates and New Strategies for Fighting against the Emerging Superbug Candida auris // Microorganisms, 2021,9(3),p.634. doi: 10.3390/microorganisms9030634
5. Tahmasebi H., Dehbashi S., Arabestani MR. Co-harboring of mcr-1 and β-lactamase genes in Pseudomonas aeruginosa by high-resolution melting curve analysis (HRMA): Molecular typing of superbug strains in bloodstream infections (BSI) // Infect. Genet. Evol, 2020,85,p.104518. doi: 10.1016/j.meegid.2020.104518
6. Parmanik A., Das S., Kar B. Current Treatment Strategies Against Multidrug-Resistant Bacteria: A Review // Curr. Microbiol., 2022, Nov 3,79(12), p.388. doi: 10.1007/s00284-022-03061-7
7. Berendonk TU., Manaia CM., Merlin C., Fatta-Kassinos D. et al. Tackling antibiotic resistance: the environmental framework // Nat. Rev. Microbiol. 2015, 13, p.310–317. doi: 10.1038/nrmicro3439
8. Hernando-Amado S., Coque TM., Baquero F., Martínez JL. Defining and combating antibiotic resistance from One Health and Global Health perspectives // Nat Microbiol. 2019 Sep;4(9):1432-1442. doi: 10.1038/s41564-019-0503-9
9. Bassetti M., Vena A., Croxatto A.et al. How to manage Pseudomonas aeruginosa infections // Drugs Context, 2018, 7, 212527. doi: 10.7573/dic.212527
10. Fraile-Ribot P., Zamorano L., Orellana R. et al. Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic beta-Lactam-Resistant Mutants // Antimicrob. Agents Chemother., 2020, 64, p.165-170. doi: 10.1128/AAC.02165-19
11. Pang Z., Raudonis R., GlickR, Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies // Biotechnol. Adv., 2019, 37, p. 177–192. doi: 10.1016/j.biotechadv.2018.11.013
12. Blanco P., Sanz-Garcia F., Hernando-Amado S. The development of efflux pump inhibitors to treat Gram-negative infections // Expert Opin. Drug Discov., 2018, 13, 919–931. doi: 10.1080/17460441.2018.1514386
13. Imperi F., Fiscarelli E., Visaggio D.et al. Activity and Impact on Resistance Development of Two Antivirulence Fluoropyrimidine Drugs in Pseudomonas aeruginosa // Front. Cell. Infect. Microbiol., 2019, 9, p.49. doi: 10.3389/fcimb.2019.00049
14. Ferrer-Espada R., Sanchez-Gomez S., Pitts B. et al. Permeability enhancers sensitize beta-lactamase-expressing Enterobacteriaceae and Pseudomonas aeruginosa to beta-lactamase inhibitors, thereby restoring their beta-lactam susceptibility // Int. J. Antimicrob. Agents, 2020, 56, 105986. doi: 10.1016/j.ijantimicag.2020.105986
15. Roemhild R., Gokhale, C., Dirksen P. et al. Cellular hysteresis as a principle to maximize the efficacy of antibiotic therapy // Proc. Natl. Acad. Sci. USA, 2018, 115, p.9767–9772. doi: 10.1073/pnas.1810004115
16. Hernando-Amado S., Sanz-García F., Martínez, J.L. Rapid and robust evolution of collateral sensitivity in Pseudomonas aeruginosa antibiotic-resistant mutants // Sci. Adv., 2020, 6, p.5493. doi: 10.1126/sciadv.aba5493
17. Barbosa C., Mahrt N., Bunk J., Grasser M.et al. The Genomic Basis of Rapid Adaptation to Antibiotic Combination Therapy in Pseudomonas aeruginosa // Mol. Biol. Evol., 2021, 38, 449–464. doi: 10.1093/molbev/msaa233
18. Санс-Гарсия Ф., Джил-Джил Т., Лаборда П. и др. Приход из дикой природы: мультирезистентные условно-патогенные микроорганизмы, представляющие собой первичную, не связанную с человеком среду обитания // Международный журнал молекулярных наук. 2021; 22(15), с. 8080. doi: 10.3390/ijms22158080
19. Levin-Reisman I., Brauner A., Ronin, I., Balaban N. Epistasis between antibiotic tolerance, persistence, and resistance mutations //Proc. Natl. Acad. Sci. USA, 2019, 116,p.14734–14739. doi: 10.1073/pnas.1906169116
20. Santi I, Manfredi P, Maffei E, Egli A, Jenal U.2021.Evolution of Antibiotic Tolerance Shapes Resistance Development in Chronic Pseudomonas aeruginosa Infections // mBio12:10.1128/mbio.03482-20. doi: 10.1128/mbio.03482-20